Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
KOS Markets Plans to Launch Trading Academy, Bringing Industry Experts and Experienced Traders to Global Financial Education
Laveda Lash and Brow Expands to Arlington’s Rosslyn Area With Fourth Location Opening Fall 2026
3 Ways to Slay: CurlyMe 3-In-1 Half Wig Sparks a New Hair Revolution
Report: Shein Postpones IPO to September
Bitcoin ETFs draw $517M in largest one-day inflow since early May
Crypto generated about 1% of Webull’s record $198M Q2 revenue
Poolease X1 Pool Robot Review: How Bad Can It Be?
Lululemon Senior Executive Exits in Third Recent Departure
Bumble Tried to Change Dating, but the Dating Market Forced It to Change Instead
North Korea launches missile barrage after dismissing Trump overture
Spring Hotels Announced as Official Event Accommodation Partner for Starmus VIII
LHW’s Newest Members: The August Collection 2026
Russia launches deadly missile and drone attacks on Kyiv
Ooni Koda 2 pizza oven review: serves up perfect pizzas in minutes
ADHD charity complains about Channel 4 documentary
You be the judge: should my partner stop hogging my side of the bed?
Fast-Track Vietnam Expands Airport and Urgent eVisa Support for International Travellers
When I Surrendered to My Kids, A Reflective Parenting Narrative Explores Growth Through Letting Go
The Immigrant Explores Identity Across Four Languages and Two Continents
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.